Usefulness of sheathless guiding catheters in patients with upper extremity vascular anomalies: Sheathless catheters in upper vascular anomalies.

The transradial approach (TRA) reduces hospitalisation and access-site complications as compared to the transfemoral approach. Nevertheless, the TRA technical failure rate is significantly higher compared to the transfemoral approach. The high failure rate of TRA is due to a series of factors. In particular, a wide range of anatomic vascular variants hindering procedural success may be present in patients undergoing TRA procedures. In our retrospective observational study, 1,596 consecutive patients with upper limb vascular anomalies underwent TRA between January 2006 and July 2017. We evaluate the usefulness of the sheathless guiding catheter system (SG) as compared to the conventional guiding catheter (CG). The primary study endpoint was the "procedural success" defined as successful transradial procedure (both selective cannulation of the coronary ostium in the diagnostic procedure and successful stent delivery in the interventional procedure) without access change. All SG procedures were successful, whereas only 1,274 (86%) CG procedures were successfully performed (p=0.0001). At multivariable analysis, age (p=0.001) and sheathless catheter use (p=0.001) were independent predictors of procedural success. The sheathless GC is a safe and useful system not only for small radial access but also in the presence of upper vascular anomalies and it can be used in PCI and diagnostic procedures.

Déclaration de conflit d'intérêts

F. Burzotta has been involved in advisory board meetings or has received speaker’s fees from Abbott, Abiomed, Medtronic and Biotronic. C. Trani has been involved in advisory board meetings or has received speaker’s fees from Abbott, Abiomed, Medtronic and Biotronic. C. Aurigemma has been involved in advisory board activities or has received speaker’s fees from Abbott, Abiomed, Medtronic and Biotronic. A.M. Leone has received speaker’s fees from Abbott, Abiomed and Bracco. I. Porto has been involved in advisory board activities or has received speaker’s fees from Abbott, Abiomed and Biotronic. G. Russo reports grants from Edwards Lifesciences, outside the submitted work The other authors have no conflicts of interest to declare.